For three virus seasons before the first RSV drug, nirsevimab, was approved, HRV accounted for two-thirds of as many RSV cases in children, according to a study published Feb. 7 in JAMA Pediatrics.
The researchers analyzed records from a tertiary hospital in France to find HRV-related burden, which was documented as a percentage of the RSV-related burden for the number of days of hospitalization or ventilation use. They found that the magnitude of HRV burden was 68% of RSV-related hospital admissions, 51% of RSV-related days of hospitalization, and 27% of RSV-related days of ventilation.
In November 2023, before RSV peaked, many U.S. children’s hospitals were reporting capacity surges. One in Texas saw 500 new respiratory cases a day.
In conclusion, the study authors said the findings “draw attention to challenges” to managing non-RSV infections, including HRV.
“The promised 86.5% individual efficacy of nirsevimab may not translate to an 86.5% reduction in bronchiolitis [HRV] burden,” they wrote. “Efforts must be made to include HRV in the development of multipathogen vaccines and to continue […] developing tailored protocols for home enteral nutrition and home oxygen therapy for infants with moderately severe bronchiolitis. Until then, adherence to universal preventive hygiene measures remains particularly critical.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.